Similarly, the percentages of BTLA+CD8+ T cells in tumors (76.61 ± 2.41%, n = 30) and peripheral blood (80.58 ± 1.54%, n = 60) from NSCLC patients were higher than those in nontumor tissues (64.37 ± 4.09%, n = 9) and donor peripheral blood (65.53 ± 2.67, n = 21) (Figures 5C, D). Here, CD8A is linked to non-small cell lung carcinoma.